GenKyoTex Meets Both Primary and Secondary Interim Efficacy Endpoints in Phase 2 Trial of GKT831 in Primary Biliary Cholangitis

GenKyoTex Meets Both Primary and Secondary Interim Efficacy Endpoints in Phase 2 Trial of GKT831 in Primary Biliary Cholangitis

  • After only 6 weeks of treatment, gamma glutamyl transpeptidase (GGT) levels were reduced by 23% in the 400mg BID group (p<0.01)
  • In patients with higher baseline GGT, reduction in GGT levels was even greater with 29% (p<0.01)
  • Alkaline phosphatase (ALP) levels were reduced by 17% in the 400mg BID group (p<0.001)
  • Genkyotex to hold a conference call and webcast today at 3:00 pm CET / 09:00 am EDT

Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX) announced today that its lead product candidate GKT831, a NOX1/4 inhibitor, met both the primary and secondary interim efficacy endpoints with high statistical significance after only 6 weeks of treatment. The data establish GKT831 as an attractive therapeutic option in a broad PBC population and support its development in multiple fibrotic diseases including NASH and IPF.

More information on :

https://www.genkyotex.com/images/PDF/GB/1_Press_Releases/2018/2018.11.05_Genkyotex_PR_interim_efficacy_results_FINAL_EN.pdf